Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810323 · ClinicalTrials.gov registry record
The ROAM Research Study Therapy (LTOT) Version
A clinical trial of Pulmonary Disease, Chronic Obstructive, sponsored by University of Virginia.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06810323 is a study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 100 participants, below the 1,043-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06810323, a study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to test a device being developed that can see how patients use oxygen therapy over a long period of time. This study will focus on developing a new display part called ROAM module which will be attached to your oxygen source. The display will provide easily-accessible information that can show how you interact with your supplies and the oxygen machine automatically without connecting the oxygen source to the internet or other devices.
Conditions Studied
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06810323
The ClinicalTrials.gov registry entry for NCT06810323 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,043-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (90% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 0 interventions.
NCT06810323 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06810323 about?
NCT06810323 is a clinical study titled "The ROAM Research Study Therapy (LTOT) Version". The purpose of this research is to test a device being developed that can see how patients use oxygen therapy over a long period of time. This study will focus on developing a new display part called ROAM module which will be attached to your oxygen source. The display will provide easily-accessible...
What is the current status of trial NCT06810323?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-01-14. Estimated completion is 2030-12.
What conditions does trial NCT06810323 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
Who is sponsoring clinical trial NCT06810323?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810323 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 1
-
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
RECRUITING · NA
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.